Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

Research and Innovation Action · Running

PROTO PROTO - Advanced PeRsOnalized Therapies for Osteoarthritis – TACKLING INFLAMMATION TO IMPROVE PATIENT OUTCOMES

Coordinator
Medizinische Universitaet Wien, Austria
Runs
1 January 2023 to 31 December 2027
Status
Running
EU funding
€7.4m
Total cost
€7.4m
Partners
11 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101095635

What the project is doing

In the project's own words, from its summary on CORDIS.

Osteoarthritis (OA) is the most common form of arthritis worldwide. Chronic low-grade inflammation in the articular environment causes cartilage degeneration at an early disease stage, resulting in chronic pain, disability and loss of independence due to progressive joint destruction. To date, no treatment is available to sustainably combat low-grade inflammation in early-stage OA patients. Biomechanical causes for intra-articular inflammation and OA development have been detected in specific patient groups.

The PROTO consortium strives to implement new evidence- and patient-centred treatment strategies for early- and pre-disease stages. For the first time, early-stage knee OA patients will be treated with local PLX-PAD injections, a novel allogeneic cell therapy product with distinct anti-inflammatory capacities that may halt or revert disease progression. Secondly, patients recovering from anterior cruciate ligament reconstructions with pathological gait patterns leading to knee OA, will be treated with a personalized sensor-based digital training intervention.

We intend to prevent health to disease transition by restoring physiological movement and reducing joint inflammation. To assess treatment success in early- and pre-stage OA, PROTO gathers scientific and clinical specialists who have genuinely shaped clinical, radiological and biomarker outcome parameters for OA in recent years. This will be the first time that these renowned experts join forces to analyze, stratify and compare fundamentally novel disease modifying treatment strategies for OA in one consortium.

PROTO was developed with the help of patient organizations, industry partners and research societies. Restoring physiological joint homeostasis at an early disease stage may be the key to understanding health to disease progression in OA. Targeting this ‘window of opportunity’ will fundamentally change the way OA is treated today and in the future.

Topics

Who is involved

OrganisationCityCountryRole
Medizinische Universitaet WienWienAustriaCoordinator
Paracelsus Medizinische Privatuniversitat Salzburg - PrivatstiftungSalzburgAustriaParticipant
Queensland University of Technology - Qld QutBrisbaneAustraliaAssociatedpartner
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Nordic Bioscience A/sHerlevDenmarkParticipant
Oulun YliopistoOuluFinlandParticipant
Pluri Biotech LtdHaifaIsraelParticipant
Innovation Acta SRLSienaItalyParticipant
Stichting ReumaNederlandAmsterdamNetherlandsParticipant
Kineto Tech Rehab SRLBucharestRomaniaParticipant
Be the Partner IncNorwood MaUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI